Real -world experience with anti-obesity medications treatment in children and adolescents with overweight and obesity in Israel
Authors' conclusion
AOMs demonstrate potential for weight management and cardiometabolic improvement in children with obesity, particularly among those with severe obesity and comorbidities, within real-world settings. However, the modest utilization rate highlights the need for improved accessibility and further real-world evidence to optimize treatment strategies for pediatric obesity.
Study context
- Population
- Children and adolescents aged 10–18 years with BMI above World Health Organization (WHO) thresholds for overweight or obesity, Clalit Health Services, Israel2,236 (0.7%) prescribed anti-obesity medications (AOMs)
- Participants
- 307,208 children
- Exposure
- AOM prescription vs no AOM prescription
- AOMsn = 2,236
- Outcome
- AOM prescribing patterns
Methodological detailselectronic database 2017-2024, health maintenance organization
- Electronic database 2017-2024
- Health maintenance organization
Main finding
As reported in the abstract
Prescribed AOMs
2236
0.7%
Metformin
73.8%
GLP-1 RA
24.5%
Orlistat
1.7%
Observational data: associations, not effects.
Further findings
Adherence and treatment duration by sex
- Females had higher adherence and longer treatment durations than males
BMI z-score and cardiometabolic parameters in those with ≥2 AOM purchases · during treatment and after cessation
- BMI z-scores significantly declined during treatment, with reductions in blood glucose, HbA1c, TG and total cholesterol and increases in HDL-C
- Partial regression after treatment cessation but remained improved vs baseline
- n = 1717 with ≥2 AOM purchases
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →